Physician profile
Aasma Riaz
NPI 1497981187
$2,548.92
in general payments reported to CMS, 2019-2025
23 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.00 · 2020: $145 · 2021: $237 · 2022: $263 · 2023: $426 · 2024: $813 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.60 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $396.27 | 2021-2024 | Puraply |
| Lilly USA, LLC | $265.73 | 2020-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $265.55 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $249.61 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Smith+Nephew, INC. | $179.01 | 2019-2025 | Collagenase Santyl, Renasys Go V2 Home, Renasys Touch |
| Amgen INC. | $161.72 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $146.70 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $141.99 | 2020-2025 | Trelegy Ellipta |
| Abbvie INC. | $128.41 | 2022-2025 | |
| Astellas Pharma US INC | $111.43 | 2024 | Veozah |
| Exact Sciences Corporation | $93.93 | 2024-2025 | Cologuard Collection Kit |
| Next Science LLC | $88.45 | 2025 | Blastx, Xperience |
| Convatec INC. | $61.58 | 2024 | |
| Hydrofera LLC | $53.07 | 2021-2024 | Hydrofera Blue Ready - Border |
| Kowa Pharmaceuticals America, INC. | $33.24 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.49 | 2022-2024 | |
| Mimedx Group, INC. | $28.39 | 2024 | |
| Sunovion Pharmaceuticals INC. | $24.84 | 2022 | |
| Pfizer INC. | $22.60 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.62 | 2025 | Xifaxan |
| Kci USA, INC. | $15.81 | 2020 | |
| Mylan Specialty L.P. | $15.48 | 2021 | |
| Aroa Biosurgery Incorporated | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aasma Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.